The first hip replacement surgery robot product has completed clinical follow-up
It is reported that “Jianjia Robot” has recently completed hundreds of millions of yuan in Series C financing. This round of financing was led by LYFE Capital, followed by SoftBank China Capital. Old shareholders Hillhouse Ventures and Fosun Pharma continued to raise funds. The financing amount was nearly 400 million yuan within one year. The funds raised will be used to advance the clinical trials of knee replacement surgical robots and the development and clinical registration of new products such as other surgical robots.
“Jianjia Robot” was established in 2018 and is a hard tissue surgery robot platform company. The company’s fastest-growing product hip replacement surgery robot has completed clinical enrollment and follow-up, and it is also China’s first “total hip replacement surgery robot” product to enter the NMPA special review program for innovative medical devices. It is expected to become the first domestically approved product. Joint replacement surgery robot. In addition, the company has a number of new surgical robots and other new products in the stage of development and inspection.
Dr. Xu Jing, the founder of “Jianjia Robot”, believes that the success of traditional joint replacement surgery depends very much on the experience and skills of doctors. In the future, the application of joint surgery robots will become the only breakthrough to improve the accuracy of prosthesis implantation and boost the volume of joint replacement surgery. Clinical data shows that Jianjia’s hip robot can control the final surgical error within 1mm, and the installation angle deviation within 1°, which significantly improves the accuracy of the doctor’s freehand operation and the long learning curve in the previous hip replacement surgery. Intraoperative radiation exposure and other issues throughout the year. In addition, in terms of preoperative planning, registration and calibration, the Jianjia robot has also been optimized to additionally support femoral side treatment, and as an open platform, it is compatible with prostheses from different manufacturers.
In addition, the company has a number of new surgical robots and other new products in the stage of research and development and inspection. Among them, the knee joint robot will soon carry out formal clinical trials.
Jiang Min, partner of SoftBank China Capital, said: Surgical robots have obvious clinical advantages in improving surgical accuracy and controlling complications, lowering the threshold of surgical learning, and shortening the training cycle of doctors. They have become a key development technology for surgery. . At present, there is a huge gap in the penetration rate of joint replacement between China and the United States, and the development prospects of the domestic joint replacement market are good.
Liu Yi, vice president and chairman of the medical device division of Fosun Pharma, said: The accelerated aging has brought the demand for joint replacement surgery to increase year by year. Improving the accuracy of surgery, shortening the recovery time of patients, and allowing joint replacement surgery to be carried out in more hospitals are the development goals of joint replacement surgery in recent years. Surgical robots provide effective solutions for improving the accuracy and consistency of joint replacement surgery.
It is concerned that there are companies such as Fuhua Medical, Tianzhihang, Stryker, and Intuitive Surgery in the orthopedic surgical robot track; in the field of orthopedic implants, related companies include Akcome Medical and Shandong Weigao.
Extended reading:
Focus on intelligent orthopedic surgery robots, “Jianjia Robot” completed a round B financing of over 100 million RMB
First launch | Provide precision joint replacement solutions, “Jianjia Robot” received tens of millions of yuan in Series A financing from BV Baidu Ventures